The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Plasma Aβ as a biomarker for predicting Aβ-PET status in Alzheimer’s disease：a systematic review with meta-analysis
Open accessAbstract
Objective: Amyloid-β positron emission tomography (Aβ-PET) scan has been proposed to detect amyloid-β (Aβ) deposition in the brain. However, this approach is costly and not ideal for the early diagnosis of Alzheimer’s disease. Blood-based Aβ measurement offers a scalable alternative to the costly or invasive biomarkers. The aim of this study was to statistically validate whether plasma Aβ could predict Aβ-PET status via meta-analysis. Methods: We systematically searched for eligible studies from PubMed, Embase and Cochrane Library, which reported plasma Aβ levels of amyloid-β positron emission tomography-positive (PET (+)) and amyloid-β positron emission tomography-negative (PET (−)) subjects. We generated pooled estimates using random effects meta-analyses. For any study that has significant heterogeneity, metaregression and subgroup analysis were further conducted. Publication bias was appraised by funnel plots and Egger’s test. Results: 16 studies with 3047 participants were included in the meta-analysis. Among all the enrolled studies, 10 studies reported plasma Aβ40 values, while 9 studies reported plasma Aβ42 values and 13 studies reported Aβ42/Aβ40 ratio. The pooled standardised mean difference (SMD) was 0.76 (95% CI −0.61 to 2.14, p=0.28) in the plasma Aβ40 values group. Plasma Aβ42 values group has a pooled SMD of −0.60 (95% CI −0.80 to −0.41, p<0.0001). In the plasma Aβ42/Aβ40 ratio group, the pooled SMD was −1.44 (95% CI −2.17 to −0.72, p<0.0001). Conclusion: Plasma Aβ40 values might not distinguish between PET (+) and PET (−) people. However, plasma Aβ42 values and plasma Aβ42/Aβ40 ratio could be served as independent biomarkers for predicting Aβ-PET status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The diagnostic power of the biomarkers varied in different studies.
“The diagnostic power of the biomarkers also varied in different studies49,50.”
From Integrated algorithm combining plasma biomarkers and cognitive assessments accurately predicts brain β-amyloid pathology (2023) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study
Sabri, O., Sabbagh, M. N., Seibyl, J., Barthel, H., Akatsu, H., Ouchi, Y., Senda, K., Murayama, S., Ishii, K., Takao, M., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.004 · Cited by 602
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
Janelidze, S., Teunissen, C. E., Zetterberg, H., Allué, J. A., Sarasa, L., Eichenlaub, U., Bittner, T., Ovod, V., Verberk, I. M. W., Toba, K., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3180 · Cited by 494
Gauthier, S., Feldman, H. H., Schneider, L. S., Wilcock, G. K., Frisoni, G. B., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Wischik, D. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31275-2 · Cited by 427
Review: sporadic cerebral amyloid angiopathy
Attems, J., Jellinger, K., Thal, D. R., & Van Nostrand, W. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01137.x · Cited by 371
Flagged first, then by citations
Research works printed but not linked: 36
- 10.1016/j.jalz.2011.03.003 · DOI · Paper page
- 10.1056/NEJMoa1202753 · DOI · Paper page
- 10.1093/brain/awv199 · DOI · Paper page
- Wang, 2020, Plasma pyroglutamate-modified amyloid beta differentiates amyloid pathology, Alzheimers Dement, 12, 1
- 10.1186/s13195-020-00619-0 · DOI
- Tosun D , Veitch D , Aisen P , et al . Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. Brain Commun 2021;3.doi:10.1093/braincomms/fcab008 · DOI
- WW, 2019, Brain Amyloid-β deposition and blood biomarkers in patients with clinically diagnosed alzheimer’s disease, J Alzheimer’s Dis, 69, 169, 10.3233/JAD-190056 · DOI
- Vogelgsang, 2018, Multiplex immunoassay measurement of amyloid-β 42 to amyloid-β 40 ratio in plasma discriminates between dementia due to Alzheimer's disease and dementia not due to Alzheimer's disease, Exp Brain Res, 236, 1241, 10.1007/s00221-018-5210-x · DOI
- 10.1059/0003-4819-155-8-201110180-00009 · DOI
- Hedges L , Olkin I . Statistical methods for meta-analysis. New York Academic Press, 1985.
- 10.1037//1082-989X.3.4.486 · DOI · Paper page
- 10.1136/bmj.315.7109.629 · DOI · Paper page
- Doecke, 2020, Total Aβ 42 /Aβ 40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis, Neurology, 94, e1580, 10.1212/WNL.0000000000009240 · DOI
- 10.1186/alzrt162 · DOI
- 10.1126/science.2111583 · DOI
- 10.1038/325733a0 · DOI · Paper page
- 10.1152/physrev.2001.81.2.741 · DOI · Paper page
- 10.1002/psc.2789 · DOI · Paper page
- 10.1136/jnnp.2006.100529 · DOI · Paper page
- 10.1016/S0140-6736(15)01124-1 · DOI · Paper page
- 10.1523/JNEUROSCI.22-12-04833.2002 · DOI · Paper page
- 10.1016/S1474-4422(16)00070-3 · DOI · Paper page
- 10.1016/S1474-4422(03)00530-1 · DOI · Paper page
- 10.1212/01.WNL.0000046581.81650.D0 · DOI
- 10.1001/archneurol.2011.1841 · DOI
- Vergallo, 2019, Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer’s disease, Alzheimer's & Dementia, 15, 764, 10.1016/j.jalz.2019.03.009 · DOI
- Pyun, 2021, Plasma amyloid-β oligomerization tendency predicts amyloid PET positivity, Clin Interv Aging, 16, 749, 10.2147/CIA.S312473 · DOI
- Chatterjee, 2019, Ultrasensitive detection of plasma amyloid-β as a biomarker for cognitively normal elderly individuals at risk of Alzheimer's disease, J Alzheimers Dis, 71, 775, 10.3233/JAD-190533 · DOI
- 10.2183/pjab.90.353 · DOI
- 10.1186/s13195-019-0485-0 · DOI · Paper page
- Palmqvist, 2019, Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease, EMBO Mol Med, 11, 1, 10.15252/emmm.201911170 · DOI · Paper page
- 10.1186/s13195-016-0227-5 · DOI
- 10.1186/s13195-019-0485-0 · DOI · Paper page
- Schindler, 2019, High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis, Neurology, 93, e1647, 10.1212/WNL.0000000000008081 · DOI · Paper page
- 10.1186/s13195-020-00619-0 · DOI
- West, 2021, A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis, Mol Neurodegener, 16, 1, 10.1186/s13024-021-00451-6 · DOI
Cited by
Sorted by citations
Pan, F., Huang, Y., Cai, X., Wang, Y., Guan, Y., Deng, J., Yang, D., Zhu, J., Zhao, Y., Xie, F., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00295-9 · Cited by 27
Self-citation
Metadata
- Authors
- Cheng, L., Li, W., Chen, Y., Lin, Y., Wang, B., Guo, Q., & Miao, Y.
- Affiliations
- Shanghai Jiao Tong University (CN)
- Corresponding author
- Miao, Ya
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2022-03-03
- Volume
- 93
- Issue
- 5
- Pages
- 513-520
- ISSN
- 0022-3050 (ISSN-L)
- 1468-330X
- PMC
- PMC9016262
- OpenAlex
- W4214934088
- Cited by
- 36
- References
- 10
- Citations by year
- 2026: 12 · 2025: 8 · 2024: 9 · 2023: 4 · 2022: 3
- FWCI
- 1.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Neurology Neurosurgery & Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Shanghai Natural Science Foundation (19ZR1438800)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- plasma amyloid-beta, amyloid PET, Alzheimer's disease, blood biomarkers, Aβ40, amyloid-beta 42, Aβ42/Aβ40 ratio, amyloid-beta deposition, early diagnosis
- MeSH terms
- Alzheimer Disease, Humans, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
